---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060237"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T13:32:50.586637+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q3 revenue $25.4M, net loss $21M; raises outlook, merger with SomaLogic

## Summary
- Q3 revenue $25.4M (down 1% YoY); GAAP net loss $21.0M; Non-GAAP adj. EBITDA -$10.1M.
- Instrument sales grew 14% in Q3, 47% YTD; Non-GAAP gross margin expanded 830bps to 57.0%.
- Operating cash use decreased 53% in Q3 to $12M; cash and investments $129.6M at quarter end.
- Raised 2023 financial outlook; planned merger with SomaLogic cited to enhance revenue and accelerate path to profitability.

## SEC filing metadata
- accession: 0000950170-23-060237
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000095017023060237/0000950170-23-060237-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000095017023060237/lab-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060237
- JSON: https://secwatch.observer/filing/0000950170-23-060237.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060237.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.